Literature DB >> 20497387

Incidence of hypertrophic pulmonary osteoarthropathy associated with primary lung cancer.

Miiru Izumi1, Koichi Takayama, Hidetake Yabuuchi, Koichiro Abe, Yoichi Nakanishi.   

Abstract

BACKGROUND AND
OBJECTIVE: Although the association of hypertrophic pulmonary osteoarthropathy (HPO) with lung cancer was investigated in the 1960s, the recent incidence of clinically apparent HPO is not known. Data from a large series of patients with lung cancer were analysed, in order to assess the incidence of possible HPO, based on bone scintigraphy, as well as the incidence of clinically confirmed HPO. The clinical features of confirmed HPO were also evaluated.
METHODS: The medical records of patients admitted with lung cancer between January 1986 and August 2004 were reviewed. Bone scintigraphy showing symmetrical, abnormally high uptake in joints and/or long bones was considered to be suggestive of HPO. Patients who also had finger clubbing and joint pain were considered to have a confirmed diagnosis of HPO. Clinical histories and hormone levels were then investigated in these patients, to identify possible causal factors.
RESULTS: Among the 1226 lung cancer patients, 55 (4.5%) demonstrated abnormally high uptake on bone scintigraphy, suggesting possible HPO. Ten (0.8%) patients had clubbed fingers and joint pain and were eventually confirmed as having HPO. Serum hormone concentrations were abnormally high in the patients with confirmed HPO.
CONCLUSIONS: This retrospective study indicated that 4.5% of lung cancer patients showed findings suggestive of HPO, a frequency similar to that reported previously. However, patients with HPO rarely showed the complete triad of signs. Although increased hormone concentrations may have caused the HPO, further investigation is required to confirm this.

Entities:  

Mesh:

Year:  2010        PMID: 20497387     DOI: 10.1111/j.1440-1843.2010.01769.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  12 in total

Review 1.  [Hypertrophic osteoarthropathy. Bamberger-Marie disease].

Authors:  B Manger; A Lindner; K Manger; J Wacker; G Schett
Journal:  Z Rheumatol       Date:  2011-09       Impact factor: 1.372

2.  [Bronchial carcinoma and knee pain. Secondary hypertrophic osteoarthropathy].

Authors:  A Baranowski; M Hansen
Journal:  Unfallchirurg       Date:  2013-08       Impact factor: 1.000

Review 3.  Paraneoplastic syndromes in rheumatology.

Authors:  Bernhard Manger; Georg Schett
Journal:  Nat Rev Rheumatol       Date:  2014-08-19       Impact factor: 20.543

Review 4.  Paraneoplastic musculoskeletal disorders: review and update for radiologists.

Authors:  Kimia Khalatbari Kani; Jack A Porrino; Michael E Mulligan; Felix S Chew
Journal:  Skeletal Radiol       Date:  2022-05-23       Impact factor: 2.199

5.  Hypertrophic Osteoarthropathy and Follicular Thyroid Cancer: A Rare Paraneoplastic Syndrome.

Authors:  Martina Tavarelli; Julie Sarfati; Christian De Gennes; Julien Haroche; Camille Buffet; Cécile Ghander; Jean Marc Simon; Fabrice Ménégaux; Laurence Leenhardt
Journal:  Eur Thyroid J       Date:  2015-08-14

6.  Lung carcinoma with hypertrophic osteoarthropathy in a teenager.

Authors:  Rowan E Miller; Rowland O Illing; Jeremy S Whelan
Journal:  Rare Tumors       Date:  2011-03-30

7.  Impact of hypertrophic pulmonary osteoarthropathy on patients with lung cancer.

Authors:  Yu-Hung Fang; Chien-Chin Hsu; Meng-Jer Hsieh; Ming-Szu Hung; Ying-Huang Tsai; Yu-Ching Lin
Journal:  Onco Targets Ther       Date:  2017-10-25       Impact factor: 4.147

8.  Hypertrophic pulmonary osteoarthropathy with primary lung cancer.

Authors:  Xinyu Qian; Jing Qin
Journal:  Oncol Lett       Date:  2014-04-02       Impact factor: 2.967

9.  Secondary hypertrophic osteoarthropathy caused by non-pleural or pulmonary tumors.

Authors:  Hans-Jonas Meyer; Leonard Leifels; Andreas Gunter Bach; Alexey Surov
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

10.  Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.

Authors:  Julie R Brahmer; Hamzah Abu-Sbeih; Paolo Antonio Ascierto; Jill Brufsky; Laura C Cappelli; Frank B Cortazar; David E Gerber; Lamya Hamad; Eric Hansen; Douglas B Johnson; Mario E Lacouture; Gregory A Masters; Jarushka Naidoo; Michele Nanni; Miguel-Angel Perales; Igor Puzanov; Bianca D Santomasso; Satish P Shanbhag; Rajeev Sharma; Dimitra Skondra; Jeffrey A Sosman; Michelle Turner; Marc S Ernstoff
Journal:  J Immunother Cancer       Date:  2021-06       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.